Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus ORTIKOS.
DEXASPORIN vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid